Indication

Esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma is a primary malignant epithelial neoplasm arising from the stratified squamous epithelium that lines the lumen of the esophagus, most frequently involving the upper and middle thoracic thirds. Read more about Esophageal squamous cell carcinoma

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Esophageal squamous cell carcinoma therapies.

Showing 1–2 of 2 drugs

OPDIVO (nivolumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT ESOPHAGEAL NEOPLASM·+17
BMS PRIMARYCARE

TEVIMBRA (tislelizumab-jsgr)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·PD-L1 POSITIVE SQUAMOUS CELL CARCINOMA OF ESOPHAGUS·+5
BEONE MEDICINES
Filter & compare in the drug finder →Opens the drug finder with Esophageal squamous cell carcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Esophageal squamous cell carcinoma.

Esophageal squamous cell carcinoma is a primary malignant epithelial neoplasm arising from the stratified squamous epithelium that lines the lumen of the esophagus, most frequently involving the upper and middle thoracic thirds.

Pathophysiologically, chronic mucosal injury—often driven by significant tobacco use, heavy alcohol consumption, nutritional deficiencies, or chronic thermal irritation—induces dysplastic progression that invades the submucosa, muscularis propria, and adjacent mediastinal structures.

Clinically, affected patients are typically older adults who present late in the disease course with progressive dysphagia, odynophagia, unintentional weight loss, and potential complications from regional lymph node metastasis or local invasion.

Personalize your experience

Follow Esophageal squamous cell carcinoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it